New HIV drug shows promise for safer pregnancies
NCT ID NCT02245022
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether the HIV drug dolutegravir is safe and effective in pregnant women who have not yet been treated for HIV. Sixty women in late pregnancy were randomly assigned to receive either dolutegravir or standard HIV medicines. The goal was to measure drug levels in the mother and check for side effects, with the hope of reducing the chance of passing HIV to the baby.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dolutegravir (Tivicay)
What this could lead to
If successful, this could point toward a safer, more effective way to prevent HIV transmission from mother to baby during pregnancy and delivery.
What could go wrong
This is a small pilot study focused on drug levels, not large-scale proof of effectiveness. Results may not apply to all populations, and side effects in pregnancy are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Desmond Tutu HIV Foundation
Cape Town, Western Cape, South Africa
-
Infectious Diseases Institute
Kampala, Uganda